2024 Annual Meeting | Industry Therapeutic Update from Genentech: Moving Upstream: The Role of Interleukin-6 in MOGAD and Autoimmune Encephalitis

Date Sunday 04/14/24

Time 11:45 AM - 12:45 PM MDT Add To Calendar

Location Colorado Convention Center | Bluebird 2A

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Ivana Vodopivec, MD

Topic(s) General Neurology, Autoimmune Neurology

Learning Objectives This Industry Therapeutic Update (ITU) explores unmet needs, diagnosis, and the evolving therapeutic landscape across a spectrum of autoantibody-driven autoimmune disorders, with a focus on myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AE). Additionally, the session discusses perspectives on the diseases' pathophysiology including the potential role of interleukin-6 (IL-6) signalling.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM MDT	Speaker	Industry Therapeutic Update from Genentech: Moving Upstream: The Role of Interleukin-6 in MOGAD and Autoimmune Encephalitis

Faculty Disclosures
Ivana Vodopivec, MD	Dr. Vodopivec has received personal compensation for serving as an employee of Roche. An immediate family member of Dr. Vodopivec has received personal compensation for serving as an employee of Novartis. Dr. Vodopivec has stock in Roche.